Global B2B Pharmaceutical Sourcing · Dossier Licensing · Named-Patient Access
💬 WhatsApp · Sign in · Register
Nifurtimox bulk supplier for pharma manufacturers

Nifurtimox 30 mg, 120 mg Suppliers & Bulk Manufacturers

Available Forms: Tablet

Available Strengths: 30 mg, 120 mg

Reference Brands: Lampit (USA)

Category: Anti Viral

Nifurtimox is an antiprotozoal medicine used to treat parasitic infections, including Chagas disease and African trypanosomiasis (sleeping sickness). It works by generating toxic radicals inside the parasite, damaging its DNA and killing it.

Get Enquiry / Request Bulk Quote

Quick Response Guaranteed | Verified Suppliers

📘 Sourcing Guide

Nifurtimox — third party manufacturing & bulk supply

Nifurtimox 30 mg, 120 mg is available through PharmaTradz for wholesale and bulk supply as well as on a third party (contract) manufacturing basis. Buyers sourcing this product generally take one of three routes:

Wholesale / bulk supply Stock or scheduled supply from an existing manufacturer. The fastest route where the product is already registered in your market.
Third party manufacturing Manufactured to your specification and packed under your own brand and label — suits distributors and brand owners building a portfolio in their market.
Dossier licensing Where a CTD, EU-CTD or ACTD dossier exists it can often be licensed for filing in your name, compressing market entry from years to months.

What to include when you enquire

  • Destination market — determines which manufacturers hold the right site-level approvals
  • First order quantity and estimated annual volume
  • Whether you need a registration dossier or the product is already registered
  • Packaging, labelling and language requirements
  • Incoterms and required shelf life

Manufacturers of Nifurtimox listed on PharmaTradz hold site-level approvals across WHO-GMP, EU-GMP, USFDA, ANVISA and TGA, verified at onboarding. Narcotic drugs and controlled substances are supplied strictly against valid import and export permits issued by the competent authorities.

Request a quote for Nifurtimox →
Disclaimer: By continuing to browse, you agree to the terms of use of this website and the Trade Marks displayed, in compliance with the provisions of the Trademark Act, 1999, Section 30 and 30(1) under 'Fair use.'

The Trade Mark owner has been correctly identified under the heading Manufacturer / TM Owner as required by the Act.
Back to Listing

Frequently Asked Questions

Nifurtimox is used to treat Chagas disease, an infection caused by the parasite

Nifurtimox is a nitrofuran derivative. Its chemical structure enables it to generate reactive intermediates that selectively damage parasitic cells while minimizing harm to human cells. The formulation includes standard pharmaceutical excipients suitable for oral administration.

Common trade names include Lampit and Nifurtimox Tablets (marketed regionally under different names).

Lampit is produced by Bayer HealthCare Pharmaceuticals. Generic versions are also manufactured by multiple GMP-certified companies in different regions.

The generic name is nifurtimox.

Brand names include Lampit and Nifurtimox Tablets.

Nifurtimox is manufactured in GMP-certified facilities by Bayer and other licensed manufacturers worldwide to supply both branded and generic versions for global distribution.

Related Products

Cobicistat

Strength:
150 mg

Form: Tablets

Reference Brands: Tybost (USA/EU)

View Details
Brincidofovir

Strength:
100 mg, 10 mg/ml

Form: Tablets / Oral suspension

Reference Brands: Tembexa (USA/EU)

View Details
Lenacapavir

Strength:
300 mg, 463.5 mg/1.5 mL

Form: Tablet / Injection

Reference Brands: Yeztugo (USA), Sunlenca (USA)

View Details
Fostemsavir

Strength:
600 mg

Form: Tablets

Reference Brands: Rukobia (USA)

View Details
Enquire Now

Quick Response Guaranteed | Verified Suppliers

Subscribe to Our Newsletter

Stay updated on pharma trends and sourcing opportunities.

Please enter the correct answer.
This website uses cookies to ensure you get the best experience. By using our site, you agree to our Privacy Policy.